Login +0086-27-65522453 sales@sun-shinechem.com

AZD2281(Olaparib) Catalog No : 92801

Chemical Information

Product NameAZD2281(Olaparib)
Iupac Chemical Name1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine 
SynonymsAZD-2281;AZD 2281 
Molecular FormulaC24H23FN4O3 
Molecular Weight434.46 
SmileO=C(N1CCN(C(C2CC2)=O)CC1)C3=CC(CC4=NNC(C5=C4C=CC=C5)=O)=CC=C3F
InChiKeyFDLYAMZZIXQODN-UHFFFAOYSA-N
InChiInChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
Cas763113-22-0

Technical Data

Appearanceoff-white solid 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 6 months-80ºCin solvent 
Shipping ConditionShipped under ambient temperature 
Quality control

Description

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.

 

Chemical Structure

92801 - AZD2281(Olaparib) | CAS 763113-22-0

Package

SizePrice
Login to get price

Quick Order

Change

Contact Us